DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Read Disclaimer

Category UNCY

Unicycive Therapeutics Inc

4 FDA PDUFA Dates — Week of June 29–30, 2026

4 PDUFA plays

ARQT, LNTH and UNCY face FDA target action dates on June 29, while VRDN follows on June 30. The setup spans pediatric dermatology, nuclear medicine imaging, dialysis-related nephrology and thyroid eye disease — four very different regulatory events with very different trading profiles.

Report date: June 25, 2026
Financial data: latest Q1 2026 updates where available

FDA Pressure Builds Into Summer: Unicycive, Spero and Capricor Move Toward High-Stakes Decisions

UNCY SPRO CAPR

Unicycive, Spero and Capricor are approaching three very different regulatory moments: a phosphate-binder resubmission for dialysis patients, a partnered oral carbapenem opportunity in complicated urinary tract infection, and a rare-disease cell therapy review in Duchenne muscular dystrophy. The common thread is simple: each story now has a dated FDA catalyst, a defined risk window and a market setup that demands precision rather than hype.

Three 2026 FDA Decisions Testing Whether New Drugs Can Beat Imperfect Standards: Unicycive, Protagonist and Savara ($UNCY $PTGX $SVRA)

UNCY PTGX SVRA

A PDUFA date is easy to understand. It creates a countdown, gives traders a calendar anchor and makes a biotech story feel tradable. But the FDA date is rarely the whole thesis. In near-approval biotech, the first question is whether the drug can be approved. The second question, often more important for long-term value, is whether the drug can change behavior after approval. That second question is where many apparently clean catalyst stories become complicated.

UNCY Unicycive Therapeutics Inc

On 18 December 2025, law firm Bragar Eagel & Squire announced a new investigation into certain officers and directors of Unicycive Therapeutics. The investigation follows the securities class action already filed in August 2025 over the company’s public statements around the OLC New Drug Application and the June 2025 FDA Complete Response Letter.

In practical terms this does not change day-to-day operations, but it reinforces a clear message: the OLC NDA path and related communication are now under legal as well as regulatory scrutiny.